Banzel Oral Suspension Approved as Adjunct Therapy for Seizures
BANZEL (rufinamide) 40mg/mL oral suspension by Eisai
The FDA has approved Banzel (rufinamide; Eisai) oral suspension for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients ≥4 years old. The oral suspension formulation is bioequivalent to the already available Banzeltablet formulation on a milligram per milligram basis.
Banzel oral suspension will be available late March in a 40mg/mL concentration.